

## AG 1295

## Chemical Properties


CAS No. : 71897-07-9

Formula: C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>

Molecular Weight: 234.3

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4].
Targets(IC50)	PDGFR
In vitro	AG1295 (10 $\mu$ M, 100 $\mu$ M) significantly inhibits rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB in vitro[2]. AG 1295 inhibits PDGFR autophosphorylation with IC50s of 0.3-0.5 $\mu$ M and 0.5-1 $\mu$ M for membrane autophosphorylation assays and Swiss 3T3 cells, respectively[1].
In vivo	AG-1295 reduces neointimal formation in aortic allograft vasculopathy by inhibiting PDGFR-beta-triggered tyrosine phosphorylation[3]. AG1295 (12 mg/kg; i.p.; daily; for 14 or 21 days) significantly decreases interstitial fibrosis, as evidenced by a smaller Sirius-Red stained area, fewer macrophages, reduced ED-A+ fibronectin deposition, and fewer alpha-smooth muscle actin-positive cells[4].

## Solubility Information

Solubility	DMSO: 60 mg/mL (256.08 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	4.268 mL	21.3402 mL	42.6803 mL
5 mM	0.8536 mL	4.268 mL	8.5361 mL
10 mM	0.4268 mL	2.134 mL	4.268 mL
50 mM	0.0854 mL	0.4268 mL	0.8536 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Kovalenko M, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. *Cancer Res.* 1994 Dec 1;54(23):6106-14.

Zheng Y, et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. *Jpn J Ophthalmol.* 2003 Mar-Apr;47(2):158-65.

Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. *Transplantation.* 2002 Nov 15;74(9):1335-41.

Ludewig D, et al. PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. *Cell Tissue Res.* 2000 Jan;299(1):97-103.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481